{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://kalivir.com/#organization",
      "name": "KaliVir Immunotherapeutics",
      "url": "https://kalivir.com/",
      "description": "multiple therapies, one virus.KALIVIR is developing cutting edge, next-generation oncolytic viral immunotherapy programs for treatment of cancer. LEARN MORE NEWS AND EVENTSAugust 19, 2026 - KaliVir Immunotherapeutics Announces Closing of $14 Million Series A Extension Financing READ MORE November 19, 2025 - KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate"
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/kalivir-immunotherapeutics#asg",
      "name": "KaliVir Immunotherapeutics ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/kalivir-immunotherapeutics",
      "isPartOf": {
        "@id": "https://kalivir.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}